Literature DB >> 10428989

Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase.

J W Chisholm1, A K Gebre, J S Parks.   

Abstract

Lecithin:cholesterol acyltransferase (LCAT) is the plasma enzyme that catalyzes esterification of the sn-2 fatty acid of phospholipid to cholesterol. To facilitate the isolation of large quantities of LCAT and to assist in future structure;-function studies, LCAT containing a carboxy-terminal histidine-tag (H6) was expressed in Chinese hamster ovary cells (CHO). A high level of CHO-hLCATH6 expression ( approximately 15 mg L(-1)) was achieved over a 72-h period using 10 mm sodium butyrate to enhance transcription and PFX-CHO protein-free medium. The pure enzyme ( approximately 96%) was isolated by cobalt metal affinity chromatography with an activity yield of 82 +/- 26%. CHO-hLCATH6 and CHO-hLCAT species had identical specific activities (26 +/- 6 and 26 +/- 3 nmol CE formed microg(-1) h(-1), respectively). The enzymatic activity of CHO-hLCATH6 was stable at 4 degrees C in excess of 60 days. Substrate saturation studies, using rHDL composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), cholesterol, and apolipoprotein A-I (80:5:1) indicated that the appK(m) for CHO-hLCATH6, CHO-hLCAT, and purified plasma LCAT were nearly identical at approximately 2 microm substrate cholesterol. We conclude that carboxy-terminal histidine-tagged LCAT is a suitable replacement for both plasma LCAT and CHO-hLCAT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428989

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

1.  Enzymatic activity of Lecithin:retinol acyltransferase: a thermostable and highly active enzyme with a likely mode of interfacial activation.

Authors:  Habib Horchani; Sylvain Bussières; Line Cantin; Mustapha Lhor; Jean-Sébastien Laliberté-Gemme; Rock Breton; Christian Salesse
Journal:  Biochim Biophys Acta       Date:  2014-03-05

2.  Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL.

Authors:  Anny Mulya; Ji-Young Lee; Abraham K Gebre; Elena Y Boudyguina; Soon-Kyu Chung; Thomas L Smith; Perry L Colvin; Xian-Cheng Jiang; John S Parks
Journal:  J Lipid Res       Date:  2008-06-25       Impact factor: 5.922

3.  Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma.

Authors:  Joseph A DiDonato; Ying Huang; Kulwant S Aulak; Orli Even-Or; Gary Gerstenecker; Valentin Gogonea; Yuping Wu; Paul L Fox; W H Wilson Tang; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal:  Circulation       Date:  2013-08-22       Impact factor: 29.690

4.  A Systematic Investigation of Structure/Function Requirements for the Apolipoprotein A-I/Lecithin Cholesterol Acyltransferase Interaction Loop of High-density Lipoprotein.

Authors:  Xiaodong Gu; Zhiping Wu; Ying Huang; Matthew A Wagner; Camelia Baleanu-Gogonea; Ryan A Mehl; Jennifer A Buffa; Anthony J DiDonato; Leah B Hazen; Paul L Fox; Valentin Gogonea; John S Parks; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2016-01-21       Impact factor: 5.157

5.  Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis.

Authors:  Dana Bailey; Isabelle Ruel; Anouar Hafiane; Haley Cochrane; Iulia Iatan; Matti Jauhiainen; Christian Ehnholm; Larbi Krimbou; Jacques Genest
Journal:  J Lipid Res       Date:  2009-09-29       Impact factor: 5.922

6.  HDL size is more accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals classified as low cardiovascular risk.

Authors:  Eliane Soler Parra; Natalia Baratella Panzoldo; Vanessa Helena de Souza Zago; Daniel Zanetti Scherrer; Fernanda Alexandre; Jamal Bakkarat; Valeria Sutti Nunes; Edna Regina Nakandakare; Eder Carlos Rocha Quintão; Wilson Nadruz; Eliana Cotta de Faria; Andrei C Sposito
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.